Drug Discovery & Development

Methods and Materials for Assaying Non-SCD1 Isoforms

WARF: P05362US

Inventors: James Ntambi, Makoto Miyazaki

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing useful tools for the discovery of SCD inhibitors.

Overview

Stearoyl-CoA desaturase (SCD) is the rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids. Inhibitors of SCD may be useful therapeutics for diseases such as obesity and diabetes.

The Invention

UW-Madison researchers have developed useful tools for the discovery of SCD inhibitors. The invention consists of cDNAs for murine SCD2 and SCD3 and human SCD5, along with a stable mammalian cell line and yeast strain that express human SCD5. In addition, the invention includes SCD2, and SCD3 knockout and transgenic mice, as well as the targeting constructs used to generate the SCD1 and SCD3 transgenic mice.

Applications

- Useful in the development of SCD inhibitors

Key Benefits

- May lead to therapeutics for diseases such as obesity and diabetes

Tech Fields

- Drug Discovery & Development : Disease models
- Drug Discovery & Development : Other drug discovery & development
- Research Tools : Cell lines

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847